Cargando…
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
PURPOSE: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with FLT3-mutant acute myeloid leukemia. PATIENTS AND METHODS: Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine o...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365380/ https://www.ncbi.nlm.nih.gov/pubmed/35063965 http://dx.doi.org/10.1158/1078-0432.CCR-21-3405 |
_version_ | 1784765332455424000 |
---|---|
author | Konopleva, Marina Thirman, Michael J. Pratz, Keith W. Garcia, Jacqueline S. Recher, Christian Pullarkat, Vinod Kantarjian, Hagop M. DiNardo, Courtney D. Dail, Monique Duan, Yinghui Chyla, Brenda Potluri, Jalaja Miller, Catherine L. Wei, Andrew H. |
author_facet | Konopleva, Marina Thirman, Michael J. Pratz, Keith W. Garcia, Jacqueline S. Recher, Christian Pullarkat, Vinod Kantarjian, Hagop M. DiNardo, Courtney D. Dail, Monique Duan, Yinghui Chyla, Brenda Potluri, Jalaja Miller, Catherine L. Wei, Andrew H. |
author_sort | Konopleva, Marina |
collection | PubMed |
description | PURPOSE: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with FLT3-mutant acute myeloid leukemia. PATIENTS AND METHODS: Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine or placebo + azacitidine and a prior phase Ib study (NCT02203773) where patients were treated with venetoclax + azacitidine. Enrolled patients were ineligible for intensive therapy due to age ≥75 years and/or comorbidities. Patients on venetoclax + azacitidine received venetoclax 400 mg orally (days 1–28) and azacitidine (75 mg/m(2); days 1–7/28-day cycle). FLT3 mutation was analyzed centrally on pretreatment bone marrow aspirates. RESULTS: In the biomarker evaluable population, FLT3 mutation was detected in 42 (15%) and 22 (19%) patients in the venetoclax + azacitidine and azacitidine groups. Composite complete remission [CRc; complete remission (CR) + CR with incomplete hematologic recovery (CRi)] rates (venetoclax + azacitidine/azacitidine) for FLT3-mutant patients were 67%/36%, median duration of remission (DoR) was 17.3/5.0 months, and median OS was 12.5/8.6 months. The CRc rates among FLT3 wild-type patients were 67%/25%, median DoR 18.4/13.4 months, and median OS 14.7/10.1 months. In patients treated with venetoclax + azacitidine, CRc in patients with FLT3-ITD and FLT3-TKD was 63% and 77% and median OS was 9.9 and 19.2 months, and in comutated FLT3-ITD + NPM1 patients, CRc was 70%, median DoR was not reached, and median OS was 9.1 months. There were no unexpected toxicities in the venetoclax + azacitidine group. CONCLUSIONS: When treated with venetoclax + azacitidine, patients with FLT3 mutations and FLT3 wild-type had similar outcomes. Future analyses in larger patient populations may further define the impact of venetoclax + azacitidine in patients harboring FLT3-ITD. See related commentary by Perl and Vyas, p. 2719 |
format | Online Article Text |
id | pubmed-9365380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-93653802023-01-05 Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia Konopleva, Marina Thirman, Michael J. Pratz, Keith W. Garcia, Jacqueline S. Recher, Christian Pullarkat, Vinod Kantarjian, Hagop M. DiNardo, Courtney D. Dail, Monique Duan, Yinghui Chyla, Brenda Potluri, Jalaja Miller, Catherine L. Wei, Andrew H. Clin Cancer Res Clinical Trials: Targeted Therapy PURPOSE: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with FLT3-mutant acute myeloid leukemia. PATIENTS AND METHODS: Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine or placebo + azacitidine and a prior phase Ib study (NCT02203773) where patients were treated with venetoclax + azacitidine. Enrolled patients were ineligible for intensive therapy due to age ≥75 years and/or comorbidities. Patients on venetoclax + azacitidine received venetoclax 400 mg orally (days 1–28) and azacitidine (75 mg/m(2); days 1–7/28-day cycle). FLT3 mutation was analyzed centrally on pretreatment bone marrow aspirates. RESULTS: In the biomarker evaluable population, FLT3 mutation was detected in 42 (15%) and 22 (19%) patients in the venetoclax + azacitidine and azacitidine groups. Composite complete remission [CRc; complete remission (CR) + CR with incomplete hematologic recovery (CRi)] rates (venetoclax + azacitidine/azacitidine) for FLT3-mutant patients were 67%/36%, median duration of remission (DoR) was 17.3/5.0 months, and median OS was 12.5/8.6 months. The CRc rates among FLT3 wild-type patients were 67%/25%, median DoR 18.4/13.4 months, and median OS 14.7/10.1 months. In patients treated with venetoclax + azacitidine, CRc in patients with FLT3-ITD and FLT3-TKD was 63% and 77% and median OS was 9.9 and 19.2 months, and in comutated FLT3-ITD + NPM1 patients, CRc was 70%, median DoR was not reached, and median OS was 9.1 months. There were no unexpected toxicities in the venetoclax + azacitidine group. CONCLUSIONS: When treated with venetoclax + azacitidine, patients with FLT3 mutations and FLT3 wild-type had similar outcomes. Future analyses in larger patient populations may further define the impact of venetoclax + azacitidine in patients harboring FLT3-ITD. See related commentary by Perl and Vyas, p. 2719 American Association for Cancer Research 2022-07-01 2022-01-21 /pmc/articles/PMC9365380/ /pubmed/35063965 http://dx.doi.org/10.1158/1078-0432.CCR-21-3405 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Clinical Trials: Targeted Therapy Konopleva, Marina Thirman, Michael J. Pratz, Keith W. Garcia, Jacqueline S. Recher, Christian Pullarkat, Vinod Kantarjian, Hagop M. DiNardo, Courtney D. Dail, Monique Duan, Yinghui Chyla, Brenda Potluri, Jalaja Miller, Catherine L. Wei, Andrew H. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia |
title | Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia |
title_full | Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia |
title_fullStr | Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia |
title_full_unstemmed | Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia |
title_short | Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia |
title_sort | impact of flt3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naïve acute myeloid leukemia |
topic | Clinical Trials: Targeted Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365380/ https://www.ncbi.nlm.nih.gov/pubmed/35063965 http://dx.doi.org/10.1158/1078-0432.CCR-21-3405 |
work_keys_str_mv | AT konoplevamarina impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT thirmanmichaelj impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT pratzkeithw impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT garciajacquelines impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT recherchristian impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT pullarkatvinod impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT kantarjianhagopm impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT dinardocourtneyd impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT dailmonique impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT duanyinghui impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT chylabrenda impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT potlurijalaja impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT millercatherinel impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia AT weiandrewh impactofflt3mutationonoutcomesaftervenetoclaxandazacitidineforpatientswithtreatmentnaiveacutemyeloidleukemia |